Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Items 701–800 of 1,000
Sigal, M., Egner, M., Okada, C., Merk, D., Sengoku, T., Katoh, T., & Suga, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c13803 · Cited by 8
Exploring Metallaphotoredox Catalysis: A Synergistic Approach to Biomolecule Functionalization
Thedy, M. E. C., Hornink, M. M., Romero, E., & Molander, G. A. (2025) · ACS Catalysis · doi:10.1021/acscatal.5c06990 · Cited by 6
Baik, J., & Lee, Y. (2025) · Journal of Bone Metabolism · doi:10.11005/jbm.25.919 · Cited by 6
“[44-46] GLP-1 analogs exert multiple beneficial effects in humans, including suppression of appetite,[47] reduction of fat mass,[45] and regulation of blood glucose levels.”
A Survey and Guide to the Development of Fatty Acid‐derivatized Peptide Therapeutics
Jacobsen, M. T., Poulsen, C., Kopp, K. L., Olsen, J., & Cox, N. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch07 · Cited by 5
Molecular engineering of designer diabetes therapeutics
DeWolf, E. L., Webber, B., & Webber, M. J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114705 · Cited by 5
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Jang, Y. E., Kwon, M., Kwon, C. W., Kim, S. G., Hwang, J. S., George, N. P., Paik, S. R., Misra, S., Basith, S., Sheen, S. S., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050537 · Cited by 7
“This underscores how rational chemical modifications, combined with advanced formulation technologies, can effectively overcome the pharmacokinetic barriers typically associated with peptide drugs, leading to extended half-life, improved bioavailability, and enhanced therapeutic efficacy [14].”
Hölscher, C. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261458402 · Cited by 6
“…is that Liraglutide has a short half-life in the blood of about 10 – 14 h. 10 In contrast, Semaglutide has a half-life in the blood of about 7 days, 11,12 which is ideal for treating diabetes, but because of that, the drug does not enter the brain readily, 9,13,14 and is therefore not ideally…”
NESTOR, J. J. J., & Wang, W. (2021) · Peptide Science · doi:10.1002/pep2.24225 · Cited by 5
Probing the Binding Mechanism of Acylated Peptides to Human Serum Albumin
Hu, H., Ransdell, A. S., Qu, H., Durbin, J. D., Valenzuela, F. A., Hernandez-Buquer, S., & Gonciarz, M. D. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00018 · Cited by 5
Xu, J., Wang, S., Wu, H., Chen, D., Han, J. D. J., & Lin, Q. (2023) · Peptides · doi:10.1016/j.peptides.2023.171073 · Cited by 8
Pharmacologic Management of Obesity after Liver Transplantation: A Critical Review.
Zahrawi, F. M., Fathma, S., Mehal, W. Z., & Banini, B. A. (2023) · PubMed · Cited by 9
The Disulfide Bond-Mediated Cyclization of Oral Peptides
Yao, C., Ye, G., Yang, Q., Chen, Z., & Yang, M. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037280719231214095428 · Cited by 5
Redefining peptide therapeutics with semaglutide
Kruse, T., & Østergaard, S. (2024) · Nature Chemistry · doi:10.1038/s41557-023-01434-4 · Cited by 5
Self-citationSun, X., Yang, D., Li, Y., Shi, J., Zhang, X., & Yi, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171203 · Cited by 6
Recent Trends in Peptide Drug Discovery and Development
Madge, H. Y. R., & Muttenthaler, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00023 · Cited by 6
Wu, Y., Zhang, Z., Cai, H., Zhang, W., Zhang, L., Li, Z., Yang, L., Chen, Y., Corner, T. P., Song, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01698 · Cited by 5
Investigating Non-Covalent Interactions of Human Serum Albumin with Doxorubicin and Folic Acid
Bauer, I., & Dmitrienko, E. V. (2024) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750823600413 · Cited by 6
Supramolecular oral delivery technologies for polypeptide-based drugs
Chen, J., Liu, T., Wang, M., Lü, B., Bai, D., Shang, J., Chen, Y., & Zhang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.045 · Cited by 5
Frich, C. K., Andersen, A. H. F., Rolskov, L. A., Zuwała, K., Gajda, P., Løvschall, K. B., Dagnæs‐Hansen, F., Banda, D. H., Pietschmann, T., Tolstrup, M., et al. (2017) · ACS Macro Letters · doi:10.1021/acsmacrolett.7b00471 · Cited by 5
Gómez‐Soler, M., Olson, E. J., de la Torre, E. R., Zhao, C., Lamberto, I., Flood, D. T., Danho, W., Lechtenberg, B. C., Riedl, S. J., Dawson, P. E., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115876 · Cited by 5
Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
Natale, F., Luisi, E., Franzese, R., Mollo, N., Solimene, A., Caso, V. M., Corvino, A., Golino, P., & Cimmino, G. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050145 · Cited by 8
“Semaglutide has a half-life of 165 h in humans due, in part, to the non-covalent association with human serum albumin, which results in decreased renal clearance and protection from metabolic degradation [14,15].”
BackgroundFrom Natural Peptides to Market
Schteingart, C. D., & Lau, J. L. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.003 · Cited by 5
Self-citationJacobsen, C. B., Raavé, R., Pedersen, M. Ø., Adumeau, P., Moreau, M., Valverde, I. E., Bjørnsdottir, I., Kristensen, J. B., Grove, M. F., Raun, K., et al. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.11.006 · Cited by 6
Self-citationHamza, A., & Șaramet, G. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.383 · Cited by 8
“Semaglutide is a glucagon-like receptor agonist, sharing 94% of structural homology with the human endogenous glucagon-like peptide one, as it has two amino acid substitutions: alanine was substituted by alpha-aminoisobutyric acid in position 8 in order to obtain resistance to systemic degradation by dipeptidyl peptid…”
BackgroundZhang, J., Li, S., Dong, Y., Tang, H., He, Y., Hu, H., & Feng, J. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116725 · Cited by 5
Frimann, T. M., Ko, S. K., Harris, P., Bukrinski, J. T., & Peters, G. H. J. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2078409 · Cited by 6
“To extend the half-life of GLP-1, different peptide analogues have been designed (Deacon, 2004; Drucker & Nauck, 2006; Lau et al., 2015) using strategies that e.g. include: i) acylation of GLP-1 with fatty acid (FA) chains, ii) covalent binding to human serum albumin (HSA), iii) attachment of Fc…”
BackgroundMethodWang, Y., Chen, J., He, Y., Lv, Y., Guo, H., Zheng, Q., & Li, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16599 · Cited by 5
“30,31 Recent studies have shown that semaglutide, after amino acid modification, is more effective in crossing the blood – brain barrier and directly activating Adcyap1 + neurons in the dorsal vagus complex (DVC).”
In vivo antibody-selective conjugation technology for long-acting drugs
Kitahara, K., Rondon, A., Miller, E., Mak, H. H., Loas, A., & Pentelute, B. L. (2025) · Chem · doi:10.1016/j.chempr.2025.102705 · Cited by 4
Programmable Bio‐Derived Noncovalent Glass via Reconfigurable H‐Bonding Networks
Fan, W., Xing, R., Zhou, P., Shen, G., Cao, S., Yuan, C., & Yan, X. (2025) · Angewandte Chemie · doi:10.1002/ange.202517982 · Cited by 9
Machine learning-guided optimization of triple agonist peptide therapeutics for metabolic disease
Wong, A., Guduri, S., Chen, T.-Y., & Patel, K. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1687617 · Cited by 4
Bellaver, E. H., da Costa, I. M., Redin, E. E., Moroni, L. S., Cunico, L. P., Bourckhardt, L. E. H., Cécere, B. G. D. O., da Silva, A. S., & Kempka, A. P. (2025) · International Dairy Journal · doi:10.1016/j.idairyj.2025.106450 · Cited by 4
Qiu, B., Fan, R., Si, G., Wang, J., Wang, K., Zheng, G., & Tian, X. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118563 · Cited by 4
Forzano, I., Narciso, V., Canonico, M. E., Castiello, D. S., Florimonte, D., Manzi, L., Semplice, F., Vallone, D. M., Cristiano, S., Spinelli, A. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031108 · Cited by 5
“More recently, semaglutide emerged as an effective and safe GLP-1RAs administrable once weekly [81].”
Lysine Targeting Group‐Transfer Chimeras for Proximity Induction
Singh, S., Tran, K., Karaj, E., Mondal, B., Tian, W., Siriwongsup, S., Sindi, S. H., Dhawa, U., Pal, K., Shoba, V. M., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202512131 · Cited by 5
Chen, Y., Song, Y., Xie, Y., & Pan, J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117846 · Cited by 5
Improving incretin-mediated body weight loss via energy expenditure
Elmendorf, A. J., Douros, J. D., Knerr, P. J., & Flak, J. N. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.12.004 · Cited by 5
Cetiner, S. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s594898 · Cited by 7
“12,25 Tirzepatide, by contrast, exerts its effects through dual agonism of both GIP and GLP-1 receptors, resulting in a distinct pharmacological profile.”
Wu, B., Falsey, J. R., Netirojjanakul, C., Herberich, B., Holder, J. R., Sham, K. K. C., Aral, J., Forsythe, N., Walker, K. W., Lu, S.-C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00032 · Cited by 4
O’Connor, R. M. (2026) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2026.1805953 · Cited by 6
“Semaglutide, another modified analog of human GLP-1, is resistant to DPP-4 degradation, which enables a once-weekly injection (Lau et al., 2015).”
Kim, D.-H., Hwang, S.-K., Yoon, J.-H., Na, D. H., Park, Y.-J., Chae, Y., Chang, J., & Kim, J.-E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060680 · Cited by 4
Wang, X., Pan, Q., Yin, J., Kou, H., Liao, X., Zhang, C., Wang, Y., She, S., Zhang, L., Wang, W., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01725-4 · Cited by 5
Design and synthesis of rhamnose-modified exenatide conjugate by sortase A-mediated ligation
Li, C., Dai, S., Cao, A., Zhou, Z., & Wu, Z. (2019) · Journal of Carbohydrate Chemistry · doi:10.1080/07328303.2019.1609021 · Cited by 4
“Semaglutide is another GLP-1 agonist with better pharmacokinetics and therapeutic profiles approved in 2017 and can be used as once-a-week injection-type or oral-type reagent.([10]) Coumaglutide, in which the GLP-1 peptide covalently linked with a dicoumarol moiety, exhibited a prolonged in vivo pharmacologic properti…”
BackgroundOral semaglutide effectiveness and safety in real world practice; The REVOLUTION study
Alsheikh, A., Alshehri, A., ALZAHRANI, S. H., Jammah, A. A., Alqahtani, F., Alotaibi, M. S., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M. S., et al. (2024) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2024.100209 · Cited by 4
Li, W. (2024) · Journal of biotechnology and bioinformatics. · doi:10.33140/jbb.01.01.04 · Cited by 4
S100A8 as a potential therapeutic target for cancer metastasis
Deguchi, A., & Maru, Y. (2024) · Cancer Science · doi:10.1111/cas.16407 · Cited by 4
Kristensen, J. B., Elster, L., Lundh, M., Ballarín-González, B., Alexopoulou, F., Kræmer, M. K., Jensen, D. M., Leurs, U., Nielsen, J. C. F., Hansen, H. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84547-1 · Cited by 6
Xu, Y., & Kuipers, O. P. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00132 · Cited by 5
Pharmaceutical Analysis of Protein–Peptide Coformulations and the Influence of Polysorbates
Whiteley, J., Abrahmsén‐Alami, S., Booth, J., Mellor, S., Humphrey, J., & Waters, L. J. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00119 · Cited by 4
Yang, I. G., Kim, J. S., & Kang, M. J. (2025) · Nanomaterials · doi:10.3390/nano15181399 · Cited by 4
“These modifications enhance albumin binding, impede enzymatic degradation, and significantly extend the peptide’s half-life in circulation [5–10].”
Nauck, M. A., Gallwitz, B., & Seufert, J. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-104866 · Cited by 4
“Im Vergleich zu Liraglutid hat es in vitro eine ähnlich gute Affinität zu GLP-1-Rezeptoren, jedoch auch eine hohe Affinität zu Albumin, was zu einer Reservoirbildung in Form von albumingebundenem Semaglutid führt und so die Verweildauer im Organismus verlängert [5].”
BackgroundWang, Y., Du, J., Zou, H., Liu, Y., Zhang, Y., González, J., Chao, E., Lu, L., Yang, P., Parker, H., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201606321 · Cited by 4
Albumin-binding as a universal strategy for half-life extension
Tan, H., Sattler, M., & Zou, P. (2022) · Japan Journal of Research · doi:10.33425/2690-8077.1043 · Cited by 5
Effective Prevention of Arterial Thrombosis with Albumin-Thrombin Inhibitor Conjugates
Marcos-Contreras, O. A., Myerson, J. W., Nong, J., Brenner, J. S., Muzykantov, V. R., & Glassman, P. M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00325 · Cited by 5
Yu, H., Åstrand, M., Cheng, J. Y., Nitin, K., Hamrén, B., & Khan, A. A. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01337-0 · Cited by 4
Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges
Bhagi, M., Kaur, J., Dhar, A., & Bhat, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010287216240324050651 · Cited by 4
Molecular design of peptide therapeutics via N-terminal modification
Sürmeli, D., Dinsmore, T. C., Anchukaitis, H. M., Montanari, V., Beinborn, M., & Kumar, K. (2024) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2024.04.011 · Cited by 7
Wei, Q., Wu, Y., Jiang, X., Lu, W. P., Liu, S., & Yu, J. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117754 · Cited by 4
Prolonged Activation of the GLP-1 Receptor via Covalent Capture
Ünsal, Ö., Bacaksiz, Z. S., Khamraev, V., Montanari, V., Beinborn, M., & Kumar, K. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00039 · Cited by 5
O uso indiscriminado do Ozempic® para fins estéticos: uma revisão de literatura
Rodrigues, W. L., & da Silva, T. M. B. (2024) · COGNITIONIS Scientific Journal · doi:10.38087/2595.8801.509 · Cited by 29
Discovery of a Long-Acting Parathyroid Hormone 1–34 Analogue to Treat Hypoparathyroidism
Ruan, S., Gui-ying, Y., Dong, Y., Shangguan, W., & Lu, W. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00149 · Cited by 4
Semaglutide for the treatment of obesity
Oleszczuk, R., Kozińska, I., Gras-Ozimek, J., Kozińska, U., & Oleszczuk, A. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.08.095 · Cited by 4
“Najnowszy preparat – semaglutyd, pozbawiony jest tej niepożądanej cechy, ponieważ jego okres półtrwania wynosi 183 godziny, co pozwala chorym na przyjmowanie leku raz w tygodniu [10].”
BackgroundFuture perspectives on peptide therapeutics
Ünsal, Ö., Liu, J., Sicinski, K. M., & Kumar, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820141-1.00003-0 · Cited by 5
Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists
Zhang, X., Cai, Y., Yao, Z., Chi, H., Li, Y., Shi, J., Zhou, Z., & Sun, L. (2023) · Peptides · doi:10.1016/j.peptides.2023.170948 · Cited by 6
Misawa, T., & Demizu, Y. (2023) · ChemistrySelect · doi:10.1002/slct.202300408 · Cited by 4
Abd-Ellah, H. S., Mudududdla, R., Carter, G. P., & Baell, J. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051530 · Cited by 4
Saudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report
Alromaih, A., Alshamrani, A., Alharbi, B., Alharbi, I., Alharbi, T., Bokhari, S., Elbadawi, H., Almehthel, M. S., Alsaeed, A. H., Alyahia, K., et al. (2023) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2023.132017 · Cited by 4
Preoperative Assessment of a Patient Undergoing Bariatric Surgery
Yuan, J. J., Bangalore, R., Darwish, D., Moon, T. S., & Wadhwa, A. N. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.07.005 · Cited by 4
Exploring the Sequence Space of Antimicrobial Peptide Dendrimers
Cai, X., Capecchi, A., Olcay, B., Orsi, M., Javor, S., & Reymond, J. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202300096 · Cited by 4
GLP-1R agonists activate human hypothalamic neuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Seah, E., Chen, J., Jawahar, B., Alcaino, C., Macarelli, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.02.587825 · Cited by 4
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202405.0258.v1 · Cited by 4
Once Blind, Now We See GLP-1 Molecular Action
Mayer, J. P., Tschöp, M. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.014 · Cited by 3
“…small molecules should be viewed in the context of the advancements in peptide optimization, which have provided highly potent GLP-1 agonists with no apparent offtarget toxicity that no longer require daily injection and, more recently, the promise for oral administration (Lau et al., 2015).”
BackgroundSpinelli, R., Sanchís, I., Rietmann, Á., Húmpola, M. V., & Siano, Á. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202403202 · Cited by 4
“For example, oral semaglutide, a glucagon-like peptide-1 receptor agonist for Type 2 diabetes, highlights the transformative potential of advanced delivery systems in enhancing oral bioavailability [33].”
Wang, X., Barcellona, A. T., Nowruzi, F., Brandt, K. M., Schulte, M. C., Kruse, L. E., Dong, E., Schrum, A. G., Yolcu, E. S., & Ulery, B. D. (2025) · Molecular Systems Design & Engineering · doi:10.1039/d4me00167b · Cited by 3
Ramsing, M. L., Warming, C., & Meldal, M. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c01951 · Cited by 3
Gabery, S., Glendorf, T., Ballarín-González, B., Pedersen, K., Kruse, T., Raun, K., & Kuhre, R. E. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123845 · Cited by 4
Self-citationZhang, C., Long, L., Hu, H., Zhou, X., Mao, L. F., Wang, J., Zhang, A., Wang, Y., Yan, Y., & Mao, S. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2557938 · Cited by 3
“…renal clearance (Gallo et al. 2022). in addition, lysine (lys) is replaced with arginine (arg) at position 34 to enhance side chain stability (lau et al. 2015). these chemical modifications have extended the half-life in humans from 1 to 2 min to 165–183 h (Dhillon 2018). sustained-release…”
Zheng, N., Chen, R., Yang, L., Xu, P., Wang, X., Sun, X., Lin, Y.-X., Qiu, J., Su, X., Wang, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02893 · Cited by 4
Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights
Dayel, F. F. B. (2025) · Healthcare · doi:10.3390/healthcare13222922 · Cited by 3
“Its molecular design exhibits enhanced albumin binding and structural modifications that prolong its plasma half-life, enabling once-weekly subcutaneous dosing, while the oral formulation is taken once daily [12,13].”
Lateral Septum as a Key Integrative Regulator of Feeding: Role of the GLP ‐1/ GLP ‐ 1R System
Dib, T., Covarrubias, M. J., Escobar, A. P., Renard, G. M., Bravo, J. A., & Sotomayor‐Zárate, R. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70301 · Cited by 3
“Semaglutide and tirzepatide represent newer generations of GLP-1 analogs designed to achieve an extended half-life, enabling once-weekly administration (Lau et al. 2015).”
Pawar, S. S., Rasal, P. B., Kulkarni, K. H., & Pawar, S. B. (2025) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v15i12.7452 · Cited by 4
Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass
Castelletto, V., de Mello, L. R., Seitsonen, J. J. T., & Hamley, I. W. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.5c02669 · Cited by 3
Pharmaceutical Peptides: From Synthesis and Mechanistic Pharmacology to Future Biologic Therapeutics
Khan, M. Y., Nawaz, T., Akash, M. S. H., & Amin, A. (2026) · Pharmaceuticals · doi:10.3390/ph19060811 · Cited by 3
“In contrast, long-acting GLP-1 receptor agonists demonstrate that charge must be optimized together with hydrophobicity, linker design, enzymatic stability, and albumin binding to extend systemic exposure and improve dosing feasibility [130].”
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin, J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.003 · Cited by 3
RetractedA New Protractor Potentiates Glucagon-Like Peptide 1 with Slow-Release Depot and Long-Term Action
Jing, W., Peng, L., Song, S., Liu, J., & Tai, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02970 · Cited by 3
Semaglutide to remodel mitochondrial dynamics and mitophagy balance for vascular dementia therapy
Yang, X., Feng, P., Zhu, H., Wang, M., Li, N., Bai, B., Sun, Y., Yan, Z., Wei, W., Chang, J., et al. (2025) · View · doi:10.1002/viw.20250013 · Cited by 4
Андреевна, Л. Е., Shevelyova, M. P., Андреевна, В. А., Deryusheva, E. I., Chaplygina, A. V., Rastrygina, V. A., Валериевич, М. А., Alikova, V. D., Nazipova, A. A., Permyakova, M. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094095 · Cited by 3
“…and long-acting GLP-1R agonists (GLP-1RAs) resistant to proteolysis by DPP-4 have been developed for clinical use (reviewed in [32,35]), including exenatide (Exen), liraglutide (Lira), semaglutide (Sema), etc. 34]. with increased affinity for HSA, suitable for once-weekly administration [52].”
Wu, Y. F., Maki, M. A. A., Mani, V., Rajagopal, M. S., & Kumar, P. V. (2025) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-025-10748-5 · Cited by 4
“Lau et al. (Lau et al. 2015) reported the modification of liraglutide a GLP-1 analog with a fatty acid chain showed extended plasma half-life and allowed once-daily dosing.”
Kobalava, Z. D., & Кохан, Е. В. (2020) · Kardiologiia · doi:10.18087/cardio.2020.9.n1274 · Cited by 4
Ray, S., Kapoor, N., Deshpande, N., Chatterjee, S., Kumar, J. S., Tantia, O., Goyal, G., Mukherjee, J. J., & Singh, A. K. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2330468 · Cited by 3
“With the addition of two structural alterations, the peptide shares chemical similarities with liraglutide [56].”
BackgroundZaykov, A. N., Gelfanov, V. M., Tagmose, T. M., Demozay, D., Manfé, V., Rohlfs, R., Rivir, M., Pérez–Tilve, D., Finan, B., & DiMarchi, R. D. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00078a · Cited by 4
Structure-Based Computational Scanning of Chemical Modification Sites in Biologics
Thomas, N., Sanyal, T., Greisen, P. J., & Deibler, K. (2024) · ACS Omega · doi:10.1021/acsomega.4c05857 · Cited by 3
“15,19 We refer to the fatty acid and linker combination as the “protractor” for the remainder of this paper.”
Pan, H., Xie, Y., Lu, W., Chen, Y., Lu, Z., Zhen, J., Wang, W., & Shang, A. (2019) · RSC Advances · doi:10.1039/c9ra06771j · Cited by 3
Olesen, M. T. J., Walther, R., Poier, P. P., Dagnæs‐Hansen, F., & Zelikin, A. N. (2020) · Angewandte Chemie · doi:10.1002/ange.201916124 · Cited by 3
Koman, A. M., Przygodzka, S., Gadżała, K., Janik, I., Pliszka, M., Palacz, K. A., Kułak, K. B., Sztybór, I., Kuśmierska, M., & Chamera-Cyrek, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52659 · Cited by 2
Søgaard, A. B., Hansson, R. F., Tvilum, A., & Zelikin, A. N. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402472 · Cited by 2
Lu, X., Harada, N., Yasuda, T., Ikeguchi, E., Kobayashi, D., Denda, M., Seno, Y., Yamane, S., Yabe, D., Otaka, A., et al. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0026 · Cited by 2
Sex differences in metabolic regulation by Gi/o-coupled receptor modulation of exocytosis
Young, M., Ceddia, R. P., Gray, A. T., Reyes, D., Cassada, J. B., Ayala, J. E., McGuinness, O. P., Collins, S., & Hamm, H. E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1544456 · Cited by 2
“Therapeutics targeting G-protein coupled receptors (GPCRs) have shown promise in a wide variety of disease conditions, including aiding metabolic dysfunction, but these compounds often cause many side effects through G α subunit signaling (Lau et al., 2015; Hall et al., 2018; Bucheit et al., 2020).”
Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder
Liu, T., Shi, F., Guo, Z., Li, H., & Qin, D. (2025) · Pharmacopsychiatry · doi:10.1055/a-2550-6470 · Cited by 4
“The amino acid substitution at position 8 (alanine to α-aminoisobutyric acid) can alter the shear site of DPP-4, making the molecule resistant to DPP-4 degradation [36].”
Im, D., Lee, Y. E., Yoon, G., Goddard, W. A., Choi, T. S., & Kim, H. I. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202504640 · Cited by 2
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.